Recent studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are showing encouraging results in managing obesity and diabetes non-insulin-dependent disease. Preclinical data suggest a unique mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/